Dr. Marianne Scheel Fjording has more than 25 years of experience within pharmaceutical and biotech companies, and brings extensive knowledge about bioanalytical assay development and regulated assay validation. Her previous role was at Novo Nordisk where she was Scientific Director implementing biomarkers in clinical trials and ensuring assays were validated for the intended use of data.

Dr. Fjording is an expert in regulated bioanalysis and brings project management and regulatory guidance to the team. Dr. Fjording is a member of the Expert Working Group (EWG) for ICH M10 Bioanalytical Method Development and has previously been on the steering committee for the European Bioanalysis Forum (EBF). At EBF she was the driver of several topic teams. Dr. Fjording received her Ph.D. in intracellular signalling and MSc in biochemistry from the University of Copenhagen in Denmark.